Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences

Liver International

Volumn 36, Issue 6, 2016, Pages 837-846

  O'Brien, Alastair ^a   China, Louise ^a   Massey, Karen A ^b   Nicolaou, Anna ^b   Winstanley, Alison ^c   Newson, Justine ^a   Hobbs, Adrian ^d   Audzevich, Tatsiana ^a   Gilroy, Derek W ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bile duct ligation; Carbon tetrachloride; Eicosanoids; Immune suppression; Leucocyte trafficking

Indexed keywords

10 HYDROXYDOCOSAHEXAENOIC ACID; 12 HYDROXYEICOSAPENTAENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXYDOCOSAHEXAENOIC ACID; 13 HYDROXYOCTADECAENOIC ACID; 14 HYDROXYDOCOSAHEXAENOIC ACID; 15 HYDROXYDOCOSAHEXAENOIC ACID; 15 HYDROXYEICOSATRIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 17 HYDROXYDOCOSAHEXAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 9 HYDROXYOCTADECAENOIC ACID; CARBON TETRACHLORIDE; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; NITRIC OXIDE; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; THROMBOXANE; UNCLASSIFIED DRUG; INDUCIBLE NITRIC OXIDE SYNTHASE;

ACUTE LIVER FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CARDIOVASCULAR DISEASE; CARRAGEENAN-INDUCED PAW EDEMA; CARRAGEENAN-INDUCED PERITONITIS; CHRONIC LIVER FAILURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DECOMPENSATED LIVER CIRRHOSIS; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; INFLAMMATION; LIPIDOMICS; LIVER HISTOLOGY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; RAT; RODENT MODEL; SARCOPENIA; ANIMAL; BILE DUCT; BLOOD; C57BL MOUSE; CHOLESTASIS; DISEASE MODEL; LIGATION; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SURGERY;

ANIMALS; BILE DUCTS; CARBON TETRACHLORIDE; CHOLESTASIS; DISEASE MODELS, ANIMAL; HUMANS; LIGATION; LIVER; LIVER CIRRHOSIS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84932110585     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12876     Document Type: Article

References (29)

1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608.
2. Zatonski WA, Sulkowska U, Manczuk M, et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16: 193-201.
3. Navasa M, Fernandez J, Rodes J. Bacterial infections in liver cirrhosis. Ital J Gastroenterol Hepatol 1999; 31: 616-25.
4. Hassner A, Kletter Y, Shlag D, et al. Impaired monocyte function in liver cirrhosis. Br Med J (Clin Res Ed) 1981; 282: 1262-3.
5. Fierer J, Finley F. Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver. J Clin Invest 1979; 63: 912-21.
6. Rajkovic IWR. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology, 1986; 6: 252-62.
7. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
8. O'Brien AJ, Welch CA, Singer M, Harrison DA. Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med 2012; 38: 991-1000.
9. Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60: 250-6.
10. O'Brien AJ, Fullerton JN, Massey KA, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014; 20: 518-23.
11. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol 2010; 88: 1157-62.
12. Acevedo J, Fernandez J. New determinants of prognosis in bacterial infections in cirrhosis. World J Gastroenterol 2014; 20: 7252-9.
13. Mathews S, Xu M, Wang H, Bertola A, Gao B. Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges. Am J Physiol Gastrointest Liver Physiol 2014; 306: G819-23.
14. Wright G, Davies NA, Shawcross DL, et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007; 45: 1517-26.
15. Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol 2011; 55: 574-81.
16. Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A. Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 75-83.
17. Masoodi M, Nicolaou A. Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 3023-9.
18. O'Brien AJ, Terala D, Orie NN, et al. BK large conductance Ca(2)+-activated K+ channel-deficient mice are not resistant to hypotension and display reduced survival benefit following polymicrobial sepsis. Shock 2011; 35: 485-91.
19. Nam SW, Liu H, Wong JZ, et al. Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice. Clin Sci (Lond) 2014; 127: 519-26.
20. Licata A, Mazzola A, Ingrassia D, et al. Clinical implications of the hyperdynamic syndrome in cirrhosis. Eur J Intern Med 2014; 25: 795-802.
21. Yang J, Petersen CE, Ha CE, Bhagavan NV. Structural insights into human serum albumin-mediated prostaglandin catalysis. Protein Sci 2002; 11: 538-45.
22. Liedtke C, Luedde T, Sauerbruch TS, et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 2013; 6: 19.
23. Domenicali M, Caraceni P, Giannone F, et al. A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol 2009; 51: 991-9.
24. Lee KC, Yang YY, Wang YW, et al. Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure. Dig Dis Sci 2010; 55: 2077-85.
25. Fiuza C, Salcedo M, Clemente G, Tellado J. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000; 182: 526-33.
26. Brown S. PHE launches local authority liver disease profiles. 2014 Available at: https://www.gov.uk/government/news/phe-launches-local-authority-liver-disease-profiles. Accessed 2015 January 2015.
27. Imajo K, Yoneda M, Kessoku T, et al. Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J Mol Sci 2013; 14: 21833-57.
28. Vanheule E, Geerts AM, Van Huysse J, et al. An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. Int J Exp Pathol 2008; 89: 419-32.
29. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56: 1283-92.